<SEC-DOCUMENT>0001004878-17-000162.txt : 20170706
<SEC-HEADER>0001004878-17-000162.hdr.sgml : 20170706
<ACCEPTANCE-DATETIME>20170706163414
ACCESSION NUMBER:		0001004878-17-000162
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20170706
DATE AS OF CHANGE:		20170706

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-205444
		FILM NUMBER:		17952505

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prosupp424b37-17.txt
<DESCRIPTION>PRO SUPP SERIES DD WARRANTS
<TEXT>
PROSPECTUS SUPPLEMENT                           Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplement dated December 8, 2016)    Registration No. 333-205444



                               CEL-SCI CORPORATION
                               Series DD Warrants



On June 29,  2017,  the Company  extended the  expiration  date of its Series DD
Warrants  by one month  from July 10,  2017 to August  10,  2017.  The Series DD
warrants  were issued as part of a financing on December 8, 2016. As a result of
the reverse stock split  approved by the Company's  shareholders  and adopted by
the Company's  directors,  the holders of the Series DD warrants are entitled to
purchase  1,360,960 shares of the Company's common stock at an exercise price of
$4.50 per share.





















                    Prospectus Supplement dated June 29, 2017





</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
